Bristol-Myers Squibb Company has received European Commission approval for a perioperative regimen involving neoadjuvant Opdivo® (nivolumab) combined with chemotherapy, followed by adjuvant Opdivo for the treatment of resectable, high-risk non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%. This approval is based on the results from the CheckMate-77T trial, which demonstrated improved event-free survival with this treatment compared to traditional methods. Opdivo is now the only PD-$(L)$1 inhibitor approved for both perioperative and neoadjuvant-only treatment of resectable NSCLC in the European Union. The approval is valid across all 27 EU member states, Iceland, Liechtenstein, and Norway. This development offers a new immunotherapy option for select patients, potentially altering the disease course by significantly reducing cancer recurrence risk and enhancing long-term outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.